PRIMERS: Polydopamine Radioimmunotherapy with Image-Guided Monitoring and Enhanced Release System

Area of Science:

• Nanotechnology
• Biomedical Engineering
• Radiotherapy

Background:

• Conventional cancer treatments face challenges with side effects and efficacy.
• Multifunctional nanoparticles offer potential for targeted cancer therapy and image guidance.
• There is a need for advanced systems to improve therapeutic outcomes and minimize toxicity.

Purpose of the Study:

• To introduce Polydopamine Radioimmunotherapy with Image-guided Monitoring and Enhanced (drug) Release System (PRIMERS) as a novel cancer therapy.
• To develop multifunctional nanoparticles for enhanced therapeutic efficacy and image-guided monitoring.
• To evaluate the potential of PRIMERS in overcoming current cancer treatment challenges.

Main Methods:

• Synthesis of Polydopamine (PDA) nanobowls using emulsion-induced interfacial anisotropic assembly.
• Surface modification of PDA nanobowls with high-Z material (gadolinium) for MRI contrast.
• Loading and evaluating the release efficiency of anti-cancer and immunotherapy drugs (Anti-CD40).

Main Results:

• Engineered PRIMERS function as fiducial markers for image-guided cancer therapy.
• Gadolinium-functionalized PDA nanobowls exhibit strong MRI contrast in vitro and in vivo.
• PRIMERS demonstrate efficient loading and pH-activated release of immunotherapy drugs, enhanced by radiation therapy.

Conclusions:

• PRIMERS show potential for combining radiotherapy with image-guided drug delivery.
• This technology offers a promising strategy to address current limitations in cancer treatment.
• The developed nanosystem provides opportunities for enhanced therapeutic efficacy and reduced toxicity.